Clinical-stage biotechnology company developing therapies for fibrosis and cancer based on galectin modulation.
Galecto, Inc., a clinical-stage biotechnology firm, focuses on developing molecules aimed at treating fibrosis, cancer, inflammation, and related diseases. The company’s leading product candidate, GB2064, is currently in Phase IIa clinical trials for the treatment of myelofibrosis. Additionally, Galecto is advancing GB0139, an inhaled inhibitor of galectin-3, which is in Phase IIb trials for addressing severe fibrotic lung diseases like idiopathic pulmonary fibrosis.
The company’s portfolio also includes GB1211, a selective oral galectin-3 inhibitor in Phase IIa trials for cancer treatment and in Phase Ib/IIa for fibrosis therapy. These developments underscore Galecto’s commitment to addressing life-threatening and progressive diseases through innovative therapeutic approaches. The firm's research and clinical trials focus on leveraging the role of galectin proteins to devise effective treatments for complex conditions.
Founded in 2011 and headquartered in Boston, Massachusetts, Galecto leverages its strategic location and scientific expertise to drive its mission forward. The company is dedicated to transforming the treatment landscape for fibrotic diseases and cancer, aiming to improve patient outcomes through cutting-edge biotechnology solutions.